Effects of green tea consumption on fatigue, depression and anxiety scores in COVID-19 patients

Evaluation of the effects of green tea consumption compared with black tea on the severity of symptoms, some serum marker, and fatigue, depression and anxiety scores in COVID-19 patients

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180205038626N8

Enrollment

Registered

2021-05-09

Start date

2021-04-21

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus disease. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients with Covid 19 will be consumed daily with three cups of green tea equivalent to 12 grams of green tea per day from Heshmat Fooman tea factory for four week

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: patients with COVID-19 Twice positive PCR test Age over 20 years Provide written consent to enter the study Not participating in other clinical trials no use of other types of herbal teas

Exclusion criteria

Exclusion criteria: Pregnancy or breastfeeding Obesity(body mass index more than30 kg per square meter ) History of heart attack or stroke, history of coronary bypass graft or coronary angioplasty, hospitalization history with heart failure Underlying diseases including chronic hepatitis, cirrhosis and cholestatic liver disease and severe renal failure Chronic obstructive pulmonary disease or severe pneumonia Active gastrointestinal ulcers

Design outcomes

Primary

Measure	Time frame
Severity of the viral infection clinical symptoms. Timepoint: At the beginning of the study and 7, 14 and 21 days after tea consumption. Method of measurement: The severity of clinical signs of viral infection will be detected through a respiratory rate more than 24 or a heart rate greater than 125 or the patient requires mechanical ventilation or saturation of peripheral oxygen less than 94% and also based on the patient's laboratory results including D- dimer more than 1000; creatinine phosphokinase twice the normal amount; positive troponin; progressive lymphopenia; ferritin more than 300.;Complete blood cell count and diffrential count. Timepoint: At the beginning of the study and one month later. Method of measurement: Cell counter devices.;C-reactive protein. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;Lactate dehydrogenase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer.;Creatinine phosphokinase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer.;Troponin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;D-dimer. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;Ferritin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.	—

Measure

Time frame

Severity of the viral infection clinical symptoms. Timepoint: At the beginning of the study and 7, 14 and 21 days after tea consumption. Method of measurement: The severity of clinical signs of viral infection will be detected through a respiratory rate more than 24 or a heart rate greater than 125 or the patient requires mechanical ventilation or saturation of peripheral oxygen less than 94% and also based on the patient's laboratory results including D- dimer more than 1000; creatinine phosphokinase twice the normal amount; positive troponin; progressive lymphopenia; ferritin more than 300.;Complete blood cell count and diffrential count. Timepoint: At the beginning of the study and one month later. Method of measurement: Cell counter devices.;C-reactive protein. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;Lactate dehydrogenase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer.;Creatinine phosphokinase. Timepoint: At the beginning of the study and one month later. Method of measurement: Biochemical autoanalyzer.;Troponin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;D-dimer. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.;Ferritin. Timepoint: At the beginning of the study and one month later. Method of measurement: ELISA device.

—

Secondary

Measure	Time frame
Depression score based on Patients Health Questionnaire-9. Timepoint: At the beginning of the study and one month later. Method of measurement: Patients Health Questionnaire-9.;Scale of fatigue based on Chalder Fatigue Scale (CFQ-11). Timepoint: At the beginning of the study and one month later. Method of measurement: Chalder Fatigue Scale (CFQ-11) Questionnaire.;Scale of anxiety based on State-Trait Anxiety Inventory (STAI) Questionnaire. Timepoint: At the beginning of the study and one month later. Method of measurement: State-Trait Anxiety Inventory (STAI) Questionnaire.	—

Measure

Time frame

Depression score based on Patients Health Questionnaire-9. Timepoint: At the beginning of the study and one month later. Method of measurement: Patients Health Questionnaire-9.;Scale of fatigue based on Chalder Fatigue Scale (CFQ-11). Timepoint: At the beginning of the study and one month later. Method of measurement: Chalder Fatigue Scale (CFQ-11) Questionnaire.;Scale of anxiety based on State-Trait Anxiety Inventory (STAI) Questionnaire. Timepoint: At the beginning of the study and one month later. Method of measurement: State-Trait Anxiety Inventory (STAI) Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Ahmadnia

Rasht University of Medical Sciences

zahmadnia@gums.ac.ir+98 13 3361 8177

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026